Tactile Systems Technology, Inc. Provides Revenue Guidance for the Second Quarter of 2022
May 02, 2022 at 05:00 pm EDT
Share
Tactile Systems Technology, Inc. provided revenue guidance for the second quarter of 2022. The company expects total revenue growth of approximately 10% to 15% year-over-year, driven by flat to 3% growth in the company's sales of the company's lymphedema products and $5 million to $6 million of sales of the company's Airway Clearance products, which, as a reminder, did not impact the company's sales results in the second quarter of 2021.
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company providing therapies for people with chronic disorders. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. The Company markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. The Company's Entre system is a basic pneumatic compression device. Kylee, its free mobile application, helps patients learn about lymphedema.
TACTILE SYSTEMS TECHNOLOGY, INC. 
